دورية أكاديمية
أعرض في EDS

Matrix metalloproteinase inhibition attenuates right ventricular dysfunction and improves responses to dobutamine during acute pulmonary thromboembolism.

التفاصيل البيبلوغرافية
العنوان: Matrix metalloproteinase inhibition attenuates right ventricular dysfunction and improves responses to dobutamine during acute pulmonary thromboembolism.
المؤلفون: Neto-Neves EM; Department of Pharmacology, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Brazil., Sousa-Santos O, Ferraz KC, Rizzi E, Ceron CS, Romano MM, Gali LG, Maciel BC, Schulz R, Gerlach RF, Tanus-Santos JE
المصدر: Journal of cellular and molecular medicine [J Cell Mol Med] 2013 Dec; Vol. 17 (12), pp. 1588-97. Date of Electronic Publication: 2013 Nov 06.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101083777 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1582-4934 (Electronic) Linking ISSN: 15821838 NLM ISO Abbreviation: J Cell Mol Med Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford, England : Wiley-Blackwell
Original Publication: Bucharest : "Carol Davila" University Press, 2000-
مواضيع طبية MeSH: Dobutamine/*therapeutic use , Matrix Metalloproteinase Inhibitors/*therapeutic use , Pulmonary Embolism/*complications , Pulmonary Embolism/*drug therapy , Ventricular Dysfunction, Right/*complications , Ventricular Dysfunction, Right/*drug therapy, Acute Disease ; Animals ; Blood Pressure/drug effects ; Cardiac Output/drug effects ; Dobutamine/pharmacology ; Doxycycline/pharmacology ; Doxycycline/therapeutic use ; Electrophoresis, Polyacrylamide Gel ; Heart Ventricles/drug effects ; Heart Ventricles/pathology ; Heart Ventricles/physiopathology ; Hypertension, Pulmonary/drug therapy ; Hypertension, Pulmonary/etiology ; Hypertension, Pulmonary/pathology ; Hypertension, Pulmonary/physiopathology ; Male ; Myocytes, Cardiac/drug effects ; Myocytes, Cardiac/metabolism ; Myocytes, Cardiac/pathology ; Oxidative Stress/drug effects ; Pulmonary Embolism/pathology ; Pulmonary Embolism/physiopathology ; Sheep ; Troponin I/blood ; Vascular Resistance/drug effects ; Vasodilation/drug effects ; Ventricular Dysfunction, Right/pathology ; Ventricular Dysfunction, Right/physiopathology
مستخلص: Activated matrix metalloproteinases (MMPs) cause cardiomyocyte injury during acute pulmonary thromboembolism (APT). However, the functional consequences of this alteration are not known. We examined whether doxycycline (a MMP inhibitor) improves right ventricle function and the cardiac responses to dobutamine during APT. APT was induced with autologous blood clots (350 mg/kg) in anaesthetized male lambs pre-treated with doxycycline (Doxy, 10 mg/kg/day, intravenously) or saline. Non-embolized control lambs received doxycycline pre-treatment or saline. The responses to intravenous dobutamine (Dob, 1, 5, 10 μg/kg/min.) or saline infusions at 30 and 120 min. after APT induction were evaluated by echocardiography. APT increased mean pulmonary artery pressure and pulmonary vascular resistance index by ~185%. Doxycycline partially prevented APT-induced pulmonary hypertension (P < 0.05). RV diameter increased in the APT group (from 10.7 ± 0.8 to 18.3 ± 1.6 mm, P < 0.05), but not in the Doxy+APT group (from 13.3 ± 0.9 to 14.4 ± 1.0 mm, P > 0.05). RV dysfunction on stress echocardiography was observed in embolized lambs (APT+Dob group) but not in embolized animals pre-treated with doxycycline (Doxy+APT+Dob). APT increased MMP-9 activity, oxidative stress and gelatinolytic activity in the RV. Although doxycycline had no effects on RV MMP-9 activity, it prevented the increases in RV oxidative stress and gelatinolytic activity (P < 0.05). APT increased serum cardiac troponin I concentrations (P < 0.05), doxycycline partially prevented this alteration (P < 0.05). We found evidence to support that doxycycline prevents RV dysfunction and improves the cardiac responses to dobutamine during APT.
(© 2013 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.)
References: Int J Cardiol. 2007 Jan 2;114(1):22-7. (PMID: 16650492)
Clin Chim Acta. 2008 Feb;388(1-2):184-8. (PMID: 18047836)
Chest. 1997 Jan;111(1):218-24. (PMID: 8996020)
Int J Cardiol. 2013 Apr 30;165(1):165-73. (PMID: 21917342)
Crit Care Med. 2011 Feb;39(2):357-63. (PMID: 21057315)
Circulation. 2000 Apr 18;101(15):1833-9. (PMID: 10769285)
Curr Opin Crit Care. 2012 Oct;18(5):424-31. (PMID: 22889868)
Free Radic Biol Med. 2006 Dec 15;41(12):1764-70. (PMID: 17157179)
Crit Care Med. 2007 Jan;35(1):239-45. (PMID: 17133179)
Physiol Rev. 2007 Oct;87(4):1285-342. (PMID: 17928585)
Vasc Med. 2010 Oct;15(5):419-28. (PMID: 20926501)
Eur Heart J. 2008 Jun;29(12):1569-77. (PMID: 18495689)
Eur J Pharmacol. 2011 Nov 30;670(2-3):554-60. (PMID: 21946107)
Circulation. 2005 Jul 26;112(4):544-52. (PMID: 16027249)
Mol Med. 2011 Mar-Apr;17(3-4):293-307. (PMID: 21046059)
Crit Care Med. 2013 Jul;41(7):e118-24. (PMID: 23478656)
Circulation. 2010 Nov 16;122(20):2039-47. (PMID: 21041693)
Am Heart J. 1995 Dec;130(6):1276-82. (PMID: 7484782)
Heart. 2011 Oct;97(20):1695-9. (PMID: 21791512)
J Mol Cell Cardiol. 2007 Oct;43(4):429-36. (PMID: 17854826)
Crit Care Med. 2011 Feb;39(2):349-56. (PMID: 20890187)
Curr Drug Targets. 2013 Mar;14(3):344-52. (PMID: 23316966)
Circulation. 2003 Nov 4;108(18):2191-4. (PMID: 14597581)
Naunyn Schmiedebergs Arch Pharmacol. 2012 Jul;385(7):685-96. (PMID: 22552729)
Biochem Pharmacol. 2009 Mar 1;77(5):826-34. (PMID: 19046943)
J Cardiovasc Pharmacol. 2009 Sep;54(3):246-52. (PMID: 19620882)
J Mol Cell Cardiol. 2006 Aug;41(2):296-307. (PMID: 16814320)
Nitric Oxide. 2012 Mar 31;26(3):162-8. (PMID: 22327038)
Forensic Sci Int. 2003 Jul 8;134(2-3):147-53. (PMID: 12850410)
Am J Physiol Heart Circ Physiol. 2000 May;278(5):H1414-20. (PMID: 10775117)
Cardiovasc Drugs Ther. 2013 Aug;27(4):259-67. (PMID: 23568586)
Circulation. 2005 Sep 13;112(11):1573-9. (PMID: 16144990)
J Immunol. 2007 Dec 1;179(11):7820-6. (PMID: 18025228)
Int J Exp Pathol. 2008 Oct;89(5):389-99. (PMID: 18808531)
Cardiovasc Res. 2010 Feb 1;85(3):413-23. (PMID: 19656780)
Circulation. 2002 Sep 17;106(12):1543-9. (PMID: 12234962)
Crit Care Clin. 2011 Oct;27(4):885-906, vi-vii. (PMID: 22082519)
Basic Clin Pharmacol Toxicol. 2013 Feb;112(2):103-9. (PMID: 22913757)
Anesth Analg. 2003 Aug;97(2):341-354. (PMID: 12873915)
Heart Fail Rev. 2012 May;17(3):395-409. (PMID: 21739365)
Annu Rev Pharmacol Toxicol. 2007;47:211-42. (PMID: 17129183)
Trends Cardiovasc Med. 2011 May;21(4):112-8. (PMID: 22681966)
فهرسة مساهمة: Keywords: cardiomyocyte injury; doxycycline; matrix metalloproteinases; pulmonary hypertension; pulmonary thromboembolism; right ventricular dysfunction
المشرفين على المادة: 0 (Matrix Metalloproteinase Inhibitors)
0 (Troponin I)
3S12J47372 (Dobutamine)
N12000U13O (Doxycycline)
تواريخ الأحداث: Date Created: 20131109 Date Completed: 20140710 Latest Revision: 20211021
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC3914650
DOI: 10.1111/jcmm.12163
PMID: 24199964
قاعدة البيانات: MEDLINE
الوصف
تدمد:1582-4934
DOI:10.1111/jcmm.12163